Human Milk Fortifier for Growth in Preterm Infants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate how well preterm infants grow and tolerate a new human milk fortifier added to their feedings. Researchers compare two different experimental milk fortifiers with a control product, all added to human milk. They seek infants born at or before 32 weeks with a birth weight between 700 and 1500 grams who are already being fed human milk by 21 days of life. Infants meeting these criteria may help improve nutrition options for preterm infants by participating in this trial.
As an unphased trial, this study offers a unique opportunity to advance nutritional care for preterm infants.
Will I have to stop taking my current medications?
The trial does not specify if participants must stop taking their current medications. However, infants receiving systemic steroids or probiotics at the time of randomization are excluded from the study.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that human milk fortifiers (HMFs) are generally safe for preterm babies. One study found that these fortifiers help preterm babies grow and may even improve their bone health. Another study noted that using commercial HMFs in donor milk was safe and supported growth.
However, caution is necessary. Some data suggests that giving very preterm babies too much protein can be risky. Therefore, while HMFs are helpful, the amount given should be closely monitored.
Overall, HMFs have a good safety record when used properly. Ongoing research aims to ensure they remain safe and effective for preterm infants.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for preterm infants because they aim to boost growth by enhancing breast milk with specialized human milk fortifiers. Unlike standard fortifiers, which typically use bovine-based proteins, these new products are derived from human milk, potentially offering a more natural and compatible nutritional boost for fragile infants. This human-derived approach might improve tolerance and nutritional absorption, potentially leading to better growth outcomes compared to traditional methods. By focusing on human milk fortifiers, these treatments could represent a significant advancement in neonatal nutrition, offering hope for improved development in preterm infants.
What evidence suggests that this trial's treatments could be effective for growth in preterm infants?
Research shows that adding human milk fortifiers to breast milk can help preterm babies grow better. This trial will compare different human milk fortifiers. Participants in one arm will receive the Experimental Product, a study human milk fortifier added to human milk feedings. In another arm, participants will receive the Control Product, a control human milk fortifier. Studies have found that preterm infants who receive fortified breast milk gain weight and grow in length and head size more quickly while in the hospital. Specifically, one study showed that babies given a particular human milk fortifier experienced better growth, with noticeable weight gain by the sixth week. Another study found that very low birth weight preterm infants grew faster with targeted fortification, gaining about 205.5 grams per week. These findings suggest that using a human milk fortifier can effectively support the growth of preterm infants.46789
Who Is on the Research Team?
Elizabeth Reverri, PhD, MS, RD
Principal Investigator
Abbott Nutrition
Are You a Good Fit for This Trial?
This trial is for preterm infants with a birth weight of 700g-1500g, born at ≤32 weeks gestation, and classified as appropriate for their gestational age. They must start human milk feeding by day 21 of life. Only single or twin births qualify, and parents must consent to exclusive human milk fortified with the study product.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Preterm infants are fed human milk fortifier (HMF) added to human milk feedings
Follow-up
Participants are monitored for safety and effectiveness after treatment
Hospital Discharge Monitoring
Monitoring of adverse events and growth metrics until hospital discharge
What Are the Treatments Tested in This Trial?
Interventions
- Control Product
- Experimental Product
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abbott Nutrition
Lead Sponsor
Robert B. Ford
Abbott Nutrition
Chief Executive Officer since 2020
Bachelor's degree from Boston College, MBA from UC Berkeley, Haas School of Business
Melissa Brotz
Abbott Nutrition
Chief Marketing Officer
Bachelor's degree in Journalism from Northwestern University